These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 3108381)
1. Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory. Klarnet JP; Matis LA; Kern DE; Mizuno MT; Peace DJ; Thompson JA; Greenberg PD; Cheever MA J Immunol; 1987 Jun; 138(11):4012-7. PubMed ID: 3108381 [TBL] [Abstract][Full Text] [Related]
2. Adoptively transferred antigen-specific T cells can be grown and maintained in large numbers in vivo for extended periods of time by intermittent restimulation with specific antigen plus IL-2. Chen W; Reese VA; Cheever MA J Immunol; 1990 May; 144(10):3659-66. PubMed ID: 2332628 [TBL] [Abstract][Full Text] [Related]
3. Distinct proliferative T cell clonotypes are generated in response to a murine retrovirus-induced syngeneic T cell leukemia: viral gp70 antigen-specific MT4+ clones and Lyt-2+ cytolytic clones which recognize a tumor-specific cell surface antigen. Matis LA; Ruscetti SK; Longo DL; Jacobson S; Brown EJ; Zinn S; Kruisbeek AM J Immunol; 1985 Jul; 135(1):703-13. PubMed ID: 2582053 [TBL] [Abstract][Full Text] [Related]
4. Retroviral transduction of protein kinase C-gamma into tumor-specific T cells allows antigen-independent long-term growth in IL-2 with retention of functional specificity in vitro and ability to mediate tumor therapy in vivo. Chen W; Schweins E; Chen X; Finn OJ; Cheever MA J Immunol; 1994 Oct; 153(8):3630-8. PubMed ID: 7930583 [TBL] [Abstract][Full Text] [Related]
5. Antigen-specific cultured T cells can mediate tumor therapy and provide long-term immunologic memory in vivo. Cheever MA; Klarnet JP; Peace DJ; Greenberg PD Prog Clin Biol Res; 1987; 244():49-58. PubMed ID: 3498958 [TBL] [Abstract][Full Text] [Related]
6. Helper-independent CD8+ cytotoxic T lymphocytes express IL-1 receptors and require IL-1 for secretion of IL-2. Klarnet JP; Kern DE; Dower SK; Matis LA; Cheever MA; Greenberg PD J Immunol; 1989 Apr; 142(7):2187-91. PubMed ID: 2466890 [TBL] [Abstract][Full Text] [Related]
7. Adoptive immunotherapy of a syngeneic murine leukemia with a tumor-specific cytotoxic T cell clone and recombinant human interleukin 2: correlation with clonal IL 2 receptor expression. Matis LA; Shu S; Groves ES; Zinn S; Chou T; Kruisbeek AM; Rosenstein M; Rosenberg SA J Immunol; 1986 May; 136(9):3496-501. PubMed ID: 2420893 [TBL] [Abstract][Full Text] [Related]
8. Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2. Thompson JA; Peace DJ; Klarnet JP; Kern DE; Greenberg PD; Cheever MA J Immunol; 1986 Dec; 137(11):3675-80. PubMed ID: 3491145 [TBL] [Abstract][Full Text] [Related]
9. Donor T cells can be induced to grow and survive long term in vivo without previous host immunosuppression. Chen W; Cheever MA J Immunol; 1994 May; 152(10):4767-74. PubMed ID: 8176202 [TBL] [Abstract][Full Text] [Related]
10. Generation of long-term T-lymphoid cell lines with specific cytotoxic reactivity for a syngeneic murine lymphoma. Eberlein TJ; Rosenstein M; Spiess PJ; Rosenberg SA J Natl Cancer Inst; 1982 Jul; 69(1):109-16. PubMed ID: 6980314 [TBL] [Abstract][Full Text] [Related]
11. Potential uses of interleukin 2 in cancer therapy. Cheever MA; Thompson JA; Peace DJ; Greenberg PD Immunobiology; 1986 Sep; 172(3-5):365-82. PubMed ID: 3492434 [TBL] [Abstract][Full Text] [Related]
12. Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: cytolytic T cells can mediate eradication of disseminated leukemia. Greenberg PD J Immunol; 1986 Mar; 136(5):1917-22. PubMed ID: 3485134 [TBL] [Abstract][Full Text] [Related]
13. Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells. Cheever MA; Thompson DB; Klarnet JP; Greenberg PD J Exp Med; 1986 May; 163(5):1100-12. PubMed ID: 3084700 [TBL] [Abstract][Full Text] [Related]
14. Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4-CD8- T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice. Yoshimura A; Shiku H; Nakayama E J Immunol; 1993 Jun; 150(11):4900-10. PubMed ID: 8496592 [TBL] [Abstract][Full Text] [Related]
15. Generation of lytic and proliferative lymphoid clones to syngeneic tumor: in vitro and in vivo studies. Rosenstein M; Rosenberg SA J Natl Cancer Inst; 1984 May; 72(5):1161-5. PubMed ID: 6609266 [TBL] [Abstract][Full Text] [Related]
16. Requirements for T cell recognition and elimination of retrovirally-transformed cells. Greenberg P; Klarnet J; Kern D; Okuno K; Riddell S; Cheever M Princess Takamatsu Symp; 1988; 19():287-301. PubMed ID: 2479634 [TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733 [TBL] [Abstract][Full Text] [Related]
18. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. Wang J; Saffold S; Cao X; Krauss J; Chen W J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528 [TBL] [Abstract][Full Text] [Related]
19. Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells. Berenson JR; Einstein AB; Fefer A J Immunol; 1975 Jul; 115(1):234-8. PubMed ID: 1080165 [TBL] [Abstract][Full Text] [Related]
20. Regulation of interleukin 2 receptor expression on murine cytotoxic T lymphocyte clones. Andrew ME; Braciale VL; Braciale TJ J Immunol; 1984 Feb; 132(2):839-44. PubMed ID: 6418812 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]